SOFTOX BIOFILM ERADICATOR STUDY (SBE-01) ADVANCES TO NEXT DOSE LEVEL DUE TO EXCELLENT SAFETY IN THE TREATMENT OF CHRONIC WOUNDS

SoftOx Solutions AS (SoftOx) are pleased to announce that the uptake of patients
into the SBE-01 clinical study has improved considerably the past weeks, leading
to completion of the first two dose-level cohorts. 

Due to lack of Serious Adverse Events / Adverse Events, the Safety Monitoring
Committee were unanimous on escalation to the next dose-level. Although early in
the study, we see that our solutions are well tolerated in chronic wounds and
confirm so far what was documented in previous animal models, says Glenn
Gundersen, Chief Medical Officer in SoftOx Solutions.

SBE-01 (EudraCT no. 2021-000314-42) is the first-in-man (phase I) study with the
SoftOx' lead wound care product, SBE, designed to treat infected chronic wounds.
The study will establish a tolerable dose and treatment schedule for SBE to be
able to develop it into an effective infection-treatment solution in
problematic, non-healing wounds. 

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Glenn Gundersen, CMO SoftOx Solutions AS
Mail: [e-mail]
Phone: Front Desk: ([phone]

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

Click here for more information

© Oslo Bors ASA, source Oslo Stock Exchange